Celldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDXGet Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 168.29% from the stock’s current price.

CLDX has been the topic of a number of other reports. Citigroup started coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Read Our Latest Research Report on CLDX

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX traded up $0.35 during midday trading on Wednesday, hitting $24.97. The stock had a trading volume of 18,918 shares, compared to its average volume of 1,046,135. The firm has a market cap of $1.66 billion, a P/E ratio of -9.65 and a beta of 1.62. Celldex Therapeutics has a fifty-two week low of $22.17 and a fifty-two week high of $53.18. The company’s 50-day simple moving average is $25.66 and its 200 day simple moving average is $31.32.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Novo Holdings A S boosted its position in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Celldex Therapeutics by 293.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 21,013 shares in the last quarter. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Celldex Therapeutics during the third quarter worth about $871,000.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Featured Articles

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.